ArticleBioinformatics (Oxford, England)2026
ParaEM: antigen-aware sequence-based paratope prediction with expectation-maximization.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
motivationAccurate identification of antibody paratopes-the residues contacting the antigen-is vital for understanding antibody-antigen recognition, antibody engineering, and vaccine design. However, structure-based predictors require antibody structural inputs, which are often obtained from experimentally determined antibody-antigen complexes in benchmark settings but are generally unavailable for new sequences. Conversely, sequence-based predictors scale efficiently but remain largely antigen-agnostic, limiting their use of pair-specific antigen context.
resultsWe introduce ParaEM, an antigen-aware sequence-based paratope predictor that operates directly on antibody and antigen sequences. ParaEM leverages pretrained ESM3 embeddings to encode both sequences, augmenting antibody residues with trainable, complementarity-determining regions (CDR)-informed embeddings to introduce a biologically informed inductive bias. It models interactions via a residue-level compatibility scorer that defines latent antigen-anchor distributions. During training, a generalized Expectation-Maximization (EM) framework alternates between estimating label-conditioned posterior responsibilities (E-step) and performing gradient-based parameter updates (M-step). Evaluated across three established benchmarks, ParaEM outperforms existing sequence-based baselines in AUC-PR and achieves performance competitive with structure-based predictors without requiring explicit three-dimensional structural inputs. Ablation studies show consistent improvements from generalized EM optimization and an additional gain from CDR-informed embeddings. Antibody-side and antigen-information controls further show that antibody sequence carries substantial predictive signal, while the matching antigen provides additional predictive information. Together, these results support ParaEM as a scalable framework for incorporating matching-antigen context into sequence-based paratope prediction. AVAILABILITY AND IMPLEMENTATION: ParaEM is available at https://github.com/kimtaegyuu/ParaEM. An archival snapshot of the software corresponding to this study is available on Zenodo at DOI: 10.5281/zenodo.22157100.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.